UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 394

Sortiert nach

NanoFerrite Particle Based Radioimmunonanoparticles: Binding Affinity and In Vivo Pharmacokinetics

Bioconjugate chemistry, 2008-06, Vol.19 (6), p.1211-1218

2008

Volltextzugriff (PDF)

Radioimmunotherapy: recent results and future directions

Journal of clinical oncology, 1996-04, Vol.14 (4), p.1383-1400

1996

Volltextzugriff (PDF)

A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words

The quarterly journal of nuclear medicine and molecular imaging, 2004-12, Vol.48 (4), p.251

2004

Volltextzugriff (PDF)

Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia

International journal of oncology, 2009-02, Vol.34 (2), p.511-516

2009

Volltextzugriff (PDF)

Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma

Journal of Skin Cancer, 2013-01, Vol.2013, p.828329-8

2013

Volltextzugriff (PDF)

Practical Determination of Patient-Specific Marrow Dose Using Radioactivity Concentration in Blood and Body

The Journal of nuclear medicine (1978), 1999-12, Vol.40 (12), p.2102-2106

1999

Volltextzugriff (PDF)

Optimized Conditions for Chelation of Yttrium-90-DOTA Immunoconjugates

The Journal of nuclear medicine (1978), 1998-12, Vol.39 (12), p.2105-2110

1998

Volltextzugriff (PDF)

Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates

Cancer research (Chicago, Ill.), 1995-02, Vol.55 (4), p.878-884

1995

Volltextzugriff (PDF)

Antibody Responses to Macrocycles in Lymphoma

The Journal of nuclear medicine (1978), 1996-03, Vol.37 (3), p.451-456

1996

Volltextzugriff (PDF)

Increased survival associated with radiolabeled lym‐1 therapy for non‐hodgkin's lymphoma and chronic lymphocytic leukemia

Cancer, 1997-12, Vol.80 (S12), p.2706-2711

1997

Volltextzugriff (PDF)

Radioimmunotherapy for breast cancer using indium- 111/yttrium-90 BrE-3 : Results of a phase I clinical trial

The Journal of nuclear medicine (1978), 1997-08, Vol.38 (8), p.1180-1185

1997

Volltextzugriff (PDF)

Yttrium-90-Labeled Monoclonal Antibody for Therapy: Labeling by a New Macrocyclic Bifunctional Chelating Agent

The Journal of nuclear medicine (1978), 1990-04, Vol.31 (4), p.473-479

1990

Volltextzugriff (PDF)

Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers

The quarterly journal of nuclear medicine and molecular imaging, 2007-12, Vol.51 (4), p.304

2007

Volltextzugriff (PDF)

Prediction of Myelotoxicity Using Radiation Doses to Marrow from Body, Blood and Marrow Sources

The Journal of nuclear medicine (1978), 1997-09, Vol.38 (9), p.1374-1378

1997

Volltextzugriff (PDF)

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma

Journal of clinical oncology, 1998-10, Vol.16 (10), p.3246-3256

1998

Volltextzugriff (PDF)

Characterization of Site-Specific ScFv PEGylation for Tumor-Targeting Pharmaceuticals

Bioconjugate chemistry, 2005-01, Vol.16 (1), p.113-121

2005

Volltextzugriff (PDF)

Pharmacokinetic Characterization in Xenografted Mice of a Series of First-Generation Mimics for HLA-DR Antibody, Lym-1, as Carrier Molecules to Image and Treat Lymphoma

The Journal of nuclear medicine (1978), 2007-08, Vol.48 (8), p.1338-1347

2007

Volltextzugriff (PDF)

Monospecific bivalent scFv-SH: Effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility

Journal of immunological methods, 2006-03, Vol.310 (1), p.100-116

2006

Volltextzugriff (PDF)

Production of Soluble ScFvs with C-Terminal-Free Thiol for Site-Specific Conjugation or Stable Dimeric ScFvs on Demand

Bioconjugate chemistry, 2004-01, Vol.15 (1), p.16-26

2004

Volltextzugriff (PDF)

Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies

Clinical cancer research, 1997-08, Vol.3 (8), p.1253-1260

1997

Volltextzugriff (PDF)

Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: Bispecific antibodies for pretargeted radioimmunotherapy

Cancer biotherapy & radiopharmaceuticals, 2001-12, Vol.16 (6), p.525-535

2001

Volltextzugriff (PDF)

Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts

Clinical cancer research, 1998-10, Vol.4 (10), p.2483-2490

1998

Volltextzugriff (PDF)

Pharmacokinetics of Chimeric L6 Conjugated to Indium-111- and Yttrium-90-DOTA-Peptide in Tumor-Bearing Mice

The Journal of nuclear medicine (1978), 1995-05, Vol.36 (5), p.829-836

1995

Volltextzugriff (PDF)

Imaging for improved prediction of myelotoxicity after radioimmunotherapy

Cancer, 1997-12, Vol.80 (S12), p.2558-2566

1997

Volltextzugriff (PDF)

Prediction of Myelotoxicity Using Semi-Quantitative Marrow Image Scores

The Journal of nuclear medicine (1978), 1997-11, Vol.38 (11), p.1749-1754

1997

Volltextzugriff (PDF)

1 – 25 von 394

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(350)
Mit Volltextzugriff
(312)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(266)
Science & Technology
(232)
Life Sciences & Biomedicine
(218)
Female
(135)
Animals
(129)
Biological And Medical Sciences
(110)
Medical Sciences
(106)
Mice
(101)
Radiology, Nuclear Medicine & Medical Imaging
(99)
Oncology
(95)
Radioimmunotherapy
(88)
Male
(80)
Radionuclide Imaging
(70)
Antibodies, Monoclonal - Therapeutic Use
(66)
Middle Aged
(58)
Adult
(57)
Pharmacology. Drug Treatments
(47)
Aged
(41)
Iodine Radioisotopes - Therapeutic Use
(40)
Tumors
(39)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

NanoFerrite Particle Based Radioimmunonanoparticles: Binding Affinity and In Vivo Pharmacokinetics

Radioimmunotherapy: recent results and future directions

A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words

Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia

Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma

Practical Determination of Patient-Specific Marrow Dose Using Radioactivity Concentration in Blood and Body

Optimized Conditions for Chelation of Yttrium-90-DOTA Immunoconjugates

Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates

Antibody Responses to Macrocycles in Lymphoma

Increased survival associated with radiolabeled lym‐1 therapy for non‐hodgkin's lymphoma and chronic lymphocytic leukemia

Radioimmunotherapy for breast cancer using indium- 111/yttrium-90 BrE-3 : Results of a phase I clinical trial

Yttrium-90-Labeled Monoclonal Antibody for Therapy: Labeling by a New Macrocyclic Bifunctional Chelating Agent

Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers

Prediction of Myelotoxicity Using Radiation Doses to Marrow from Body, Blood and Marrow Sources

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma

Characterization of Site-Specific ScFv PEGylation for Tumor-Targeting Pharmaceuticals

Pharmacokinetic Characterization in Xenografted Mice of a Series of First-Generation Mimics for HLA-DR Antibody, Lym-1, as Carrier Molecules to Image and Treat Lymphoma

Monospecific bivalent scFv-SH: Effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility

Production of Soluble ScFvs with C-Terminal-Free Thiol for Site-Specific Conjugation or Stable Dimeric ScFvs on Demand

Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies

Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: Bispecific antibodies for pretargeted radioimmunotherapy

Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts

Pharmacokinetics of Chimeric L6 Conjugated to Indium-111- and Yttrium-90-DOTA-Peptide in Tumor-Bearing Mice

Imaging for improved prediction of myelotoxicity after radioimmunotherapy

Prediction of Myelotoxicity Using Semi-Quantitative Marrow Image Scores

Suchergebnisse filtern